SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 5,915.68 |
| Enterprise Value ($M) | 5,219.53 |
| Book Value ($M) | 1,826.19 |
| Book Value / Share | 11.09 |
| Price / Book | 3.24 |
| NCAV ($M) | 1,643.77 |
| NCAV / Share | 9.98 |
| Price / NCAV | 3.60 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.23 |
| Return on Assets (ROA) | -0.41 |
| Return on Equity (ROE) | -0.46 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 13.06 |
| Current Ratio | 13.06 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,879.28 |
| Assets | 2,061.70 |
| Liabilities | 235.51 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 11.58 |
| Operating Income | -461.69 |
| Net Income | -436.37 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -350.57 |
| Cash from Investing | -342.60 |
| Cash from Financing | 1,229.20 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Biotechnology Value Fund L P | 3.60 | -20.84 | |
| 13G/A | EcoR1 Capital, LLC | 0.10 | -98.16 | |
| 13G/A | Vanguard Group Inc | 8.93 | 93.53 | |
| 13G/A | Bb Biotech Ag | 3.10 | 5.63 | |
| 13G/A | Farallon Capital Partners, L.P. | 4.10 | -0.18 | |
| 13G/A | Column Group Iii, Lp | 0.00 | -100.00 | |
| 13G/A | Wellington Management Group Llp | 9.09 | 4.66 | |
| 13G/A | BlackRock Inc. | 7.90 | 97.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 91,883 | 1,013,096 | 9.07 | |
| 235,765 | 1,017,261 | 23.18 | |
| 258,853 | 1,283,498 | 20.17 | |
| 195,852 | 484,116 | 40.46 | |
| 112,829 | 469,139 | 24.05 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ROIV – Roivant Sciences Ltd. | RPRX – Royalty Pharma plc |
| RPTX – Repare Therapeutics Inc. | RXRX – Recursion Pharmaceuticals, Inc. |
| SANA – Sana Biotechnology, Inc. |
Financial data and stock pages provided by
Fintel.io